Clinical and urodynamic effects of tolterodine in women with an overactive bladder.
OBJECTIVE
The aim of this study was to compare the changes in urinary symptoms and urodynamic parameters after administration of tolterodine in women with an overactive bladder (OAB).


METHODS
Thirty-eight women diagnosed with OAB and treated with tolterodine were reviewed. Urinalysis, pelvic examination, 3-day bladder diary, urodynamic study, and a personal interview to identify urinary symptoms prior to and 3 months after treatment were recorded and interpreted.


RESULTS
Most of our patients were menopausal (76.3%; mean age 55.7 years) and multiparous (mean parity 3.3) women. Urinary symptoms such as urinary frequency, urgency, urge incontinence, and nocturia were decreased significantly (p < 0.05). All urodynamic parameters did not change significantly except for the maximum cystometric capacity (p < 0.05), showing a significant increase after 3 months of medication.


CONCLUSIONS
Tolterodine, at a recommended dose, improves the symptoms of OAB syndrome without causing urine retention, as proved by the changes of urodynamic parameters.
Department of Obstetrics and Gynecology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chiu-Lin
CL
Wang
Chin-Hu
CH
Wu
Cheng-Min
CM
Liu
Ching-Ju
CJ
Shen
Kun-Ling
KL
Lin
Cheng-Yu
CY
Long
D000328:Adult; D000368:Aged; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D003408:Cresols / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D053158:Nocturia / Q000188:drug therapy; D010298:Parity; D010665:Phenylpropanolamine / Q000008:administration & dosage*; D011247:Pregnancy; D012189:Retrospective Studies; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D053202:Urinary Incontinence, Urge / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects*; D064804:Urological Agents / Q000008:administration & dosage*
D001559:Benzhydryl Compounds; D003408:Cresols; D064804:Urological Agents; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate
overactive bladder; tolterodine; urodynamic study